NCT07573735 Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
| NCT ID | NCT07573735 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongda Hospital |
| Condition | Atopic Dermatitis (Eczema) |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2026-02-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage. While researchers know that the immune system is overactive in AD, it is difficult to measure the exact level of "damage" or "inflammation" happening deep within the skin using only a physical exam. The Purpose of This Study This study investigates a specific "danger signal" called circulating cell-free DNA (cfDNA). When skin cells are damaged or die due to inflammation, they release tiny fragments of DNA into the bloodstream. The investigators believe these fragments might act as a trigger for the immune system, worsening the disease. What the Study Involves Researchers will collect blood samples and small skin biopsies from patients with AD and healthy volunteers. The study aims to: Compare the levels of cfDNA in the blood of AD patients versus healthy individuals. Determine if higher levels of cfDNA correlate with more severe skin symptoms (measured by scores like SCORAD and EASI). Examine how immune cells in the skin (macrophages) respond to these DNA fragments through a specific biological switch called the STING pathway. Potential Impact By understanding this "damage-signal" loop, this research may lead to new ways for doctors to monitor AD severity through simple blood tests and could identify new targets for future anti-inflammatory treatments.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Confirmed diagnosis of Atopic Dermatitis Exclusion Criteria: * Use of systemic immunosuppressants, systemic corticosteroids, or biological agents within 4 weeks prior to enrollment * Use of topical treatments within 2 weeks prior to enrollment
Frequently Asked Questions
Who can join the NCT07573735 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis (Eczema). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07573735 currently recruiting?
Yes, NCT07573735 is actively recruiting participants. Visit ClinicalTrials.gov or contact Zhongda Hospital to inquire about joining.
Where is the NCT07573735 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07573735 clinical trial?
NCT07573735 is sponsored by Zhongda Hospital. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.